OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
PAR:OSE
Price:
6.15
EUR
1.65%
Market Closed
Market Cap:
134.9m
EUR
Cash Flow Statement
Cash Flow Statement
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA
Currency: EUR
Millions
TTM
| Dec-2014 | Jun-2015 | Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Sep-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||||||||||||
| Net Income |
(3)
|
(5)
|
(6)
|
22
|
21
|
(10)
|
(11)
|
5
|
5
|
(3)
|
(5)
|
(8)
|
(17)
|
(25)
|
(16)
|
(17)
|
(7)
|
(18)
|
(28)
|
(23)
|
46
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
3
|
4
|
4
|
4
|
3
|
3
|
|
| Other Non-Cash Items |
0
|
1
|
2
|
(19)
|
(20)
|
(1)
|
(1)
|
1
|
0
|
2
|
5
|
(2)
|
(0)
|
5
|
3
|
4
|
1
|
(1)
|
(1)
|
1
|
1
|
|
| Cash Taxes Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
|
| Change in Working Capital |
1
|
0
|
(1)
|
(8)
|
0
|
15
|
3
|
(8)
|
(5)
|
8
|
8
|
(4)
|
(3)
|
3
|
(0)
|
1
|
(3)
|
(3)
|
(3)
|
(1)
|
8
|
|
| Cash from Operating Activities |
(2)
N/A
|
(3)
-74%
|
(5)
-37%
|
(5)
-16%
|
1
N/A
|
4
+469%
|
(8)
N/A
|
(2)
+77%
|
1
N/A
|
8
+647%
|
9
+14%
|
(14)
N/A
|
(19)
-39%
|
(17)
+14%
|
(12)
+30%
|
(10)
+15%
|
(5)
+47%
|
(18)
-248%
|
(28)
-54%
|
(20)
+30%
|
58
N/A
|
|
| Investing Cash Flow | ||||||||||||||||||||||
| Capital Expenditures |
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
|
| Other Items |
0
|
(0)
|
(6)
|
(3)
|
6
|
3
|
0
|
0
|
0
|
(0)
|
3
|
3
|
(0)
|
0
|
(0)
|
(0)
|
(1)
|
0
|
0
|
(0)
|
(55)
|
|
| Cash from Investing Activities |
(0)
N/A
|
(0)
-1 300%
|
(6)
-1 681%
|
(3)
+57%
|
6
N/A
|
3
-53%
|
(0)
N/A
|
(1)
-126%
|
(1)
+17%
|
(0)
+17%
|
2
N/A
|
2
-5%
|
(1)
N/A
|
0
N/A
|
(1)
N/A
|
(1)
-28%
|
(1)
-31%
|
0
N/A
|
0
+231%
|
(1)
N/A
|
(56)
-10 853%
|
|
| Financing Cash Flow | ||||||||||||||||||||||
| Net Issuance of Common Stock |
3
|
20
|
20
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
17
|
18
|
17
|
0
|
0
|
0
|
0
|
11
|
11
|
|
| Net Issuance of Debt |
0
|
1
|
1
|
(1)
|
(1)
|
2
|
3
|
1
|
(0)
|
0
|
5
|
11
|
6
|
4
|
5
|
15
|
10
|
10
|
11
|
2
|
(4)
|
|
| Other |
0
|
(2)
|
(2)
|
(0)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
1
|
|
| Cash from Financing Activities |
3
N/A
|
19
+595%
|
19
-1%
|
(1)
N/A
|
(1)
+0%
|
2
N/A
|
3
+69%
|
1
-79%
|
(1)
N/A
|
0
N/A
|
5
+1 996%
|
11
+130%
|
23
+113%
|
21
-11%
|
22
+6%
|
15
-32%
|
10
-31%
|
10
+0%
|
12
+15%
|
13
+13%
|
8
-40%
|
|
| Change in Cash | ||||||||||||||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Change in Cash |
1
N/A
|
16
+1 812%
|
8
-47%
|
(9)
N/A
|
6
N/A
|
9
+54%
|
(5)
N/A
|
(2)
+64%
|
(0)
+96%
|
8
N/A
|
16
+108%
|
(1)
N/A
|
4
N/A
|
4
+23%
|
10
+122%
|
4
-56%
|
4
-7%
|
(8)
N/A
|
(16)
-103%
|
(7)
+57%
|
11
N/A
|
|
| Free Cash Flow | ||||||||||||||||||||||
| Free Cash Flow |
(2)
N/A
|
(3)
-72%
|
(5)
-38%
|
(5)
-16%
|
1
N/A
|
4
+487%
|
(8)
N/A
|
(3)
+69%
|
0
N/A
|
8
+1 486%
|
9
+15%
|
(14)
N/A
|
(19)
-38%
|
(17)
+13%
|
(12)
+29%
|
(10)
+13%
|
(6)
+45%
|
(19)
-223%
|
(28)
-51%
|
(20)
+29%
|
58
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
